RIA Advisory Group LLC Purchases New Position in Pfizer Inc. (NYSE:PFE)

RIA Advisory Group LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 12,900 shares of the biopharmaceutical company’s stock, valued at approximately $371,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RB Capital Management LLC increased its stake in Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its stake in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares during the period. United Bank increased its stake in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the period. Ergoteles LLC increased its stake in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp increased its stake in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Price Performance

PFE traded up $0.61 on Friday, hitting $26.00. 37,924,934 shares of the company were exchanged, compared to its average volume of 42,423,668. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37. The firm has a market capitalization of $147.23 billion, a P/E ratio of 72.22, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The business’s fifty day moving average is $27.14 and its 200 day moving average is $28.74.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm earned $1.14 earnings per share. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.